The company has developed a proprietary technology platform, ExoPheno™, which integrates wet lab and dry lab technologies to provide next-generation multi-omics liquid biopsy tests. By analyzing the bioactivity of tissue-specific exosomes in real-time, medical professionals can detect cancer cells and provide better treatment to patients. Mursla's technology platform, which includes novel nanoelectronics NEXOS, is designed to identify the multi-omics cargo of exosomes, including DNA, RNA, proteins, lipids, and metabolites, in order to reflect the state of their cellular sources. This breakthrough technology has the potential to revolutionize the field of liquid biopsy testing and improve patient outcomes.